PRLD Overview

Prelude Therapeutics Incorporated is a precision oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. By focusing on developing molecules using broad mechanisms that have multiple links to oncogenic driver pathways in select patients, it has developed a diverse pipeline consisting of multiple distinct programs, including kinases, targeted protein degraders, and degrader antibody conjugates. PRT12396 its lead, mutant-selective JAK2V617F inhibitor, is an open-label and multi-center study in patients with high-risk polycythemia vera and intermediate and high-risk myelofibrosis. JAK2V617F is the primary driver mutation responsible for disease progression in the majority of patients living with myeloproliferative neoplasms. The Company has discovered and is developing a series of selective and orally bioavailable KAT6A selective degraders. KAT6A is engaged in treating advanced breast cancer & other solid tumors.

Wall Street analysts forecast PRLD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRLD is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Prelude Therapeutics Inc revenue for the last quarter amounts to 5.64M USD, increased 41.00

Prelude Therapeutics Inc. EPS for the last quarter amounts to -0.21 USD, decreased -44.74

Prelude Therapeutics Inc (PRLD) has 79 emplpoyees as of April 24 2026.

Today PRLD has the market capitalization of 356.49M USD.